Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation

Promoter Disclosed Acquisition PlansCfo Debt Reduction RoadmapInvestor Communications View source PDF

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+8.1%1-day move

₹1618.50

prior close

₹1625.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+4.5+4.5+3.2+7.1+8.1+9.5+11.8+12.6+12.3+13.3+16.4+13.7+15.7+21.9

Up moveDown movePending

AI summary

Sun Pharma announced its acquisition of Organon & Co for $14.0 per share in cash, representing an equity value of $3.99 billion and enterprise value of $11.75 billion. The deal will be financed with $2-2.5 billion of cash on hand and the balance through committed bank financing. The combined entity would have $12.4 billion in revenue and $3.7 billion in EBITDA, nearly doubling Sun Pharma's current scale. Sun Pharma expects potential synergies of over $350 million in 2-4 years. The transaction is expected to close in early 2027, subject to Organon shareholder and regulatory approvals.

Likely market impact

This is a transformative acquisition that will make Sun Pharma a top 25 global pharma company with diversified revenue streams across Innovative Medicines, Established Brands, and Biosimilars, while significantly expanding its global commercial footprint.